How much do GLP-1 treatments cost in France? Wegovy®, Ozempic® and Mounjaro® can cost between €60 and €400 per month, without reimbursement for the obesity indication. This cost now represents one of the main barriers to access and treatment continuity.

GLP-1 receptor agonists have transformed the management of obesity. Their efficacy is documented, their mechanism of action well understood, and clinical results are often significant. But a reality is emerging in daily practice: the cost of GLP-1 treatments in France constitutes a major barrier to obesity care.

Until 15 June 2026, GLP-1s prescribed for obesity were not reimbursed in France. Since that date, Wegovy® and Mounjaro® are reimbursed by the national health insurance under restricted conditions (BMI ≥ 40, or ≥ 35 with at least one obesity-related comorbidity). For the majority of patients within the marketing authorisation scope — including the entire BMI 27-35 range — the full cost remains borne by the patient. And when treatment stops for financial reasons, the consequences are the same as for any other reason for discontinuation: the return of appetite and weight regain.

This article examines the economic reality of GLP-1 treatments in France, the consequences for care pathways, and the question that follows: how can we structure sustainable support when the pharmacological lever is no longer accessible?

GLP-1 pricing in France: how much do treatments cost in 2026?

GLP-1 prices vary depending on the molecule, dosage and pharmacy. In France, pricing is unregulated for medications not reimbursed by the national health insurance — so it can differ from one pharmacy to another. Here are the approximate ranges observed in 2026 (these ranges remain the reference for patients outside the reimbursed pathway):

In summary, GLP-1 treatments require prolonged — often indefinite — use, which considerably amplifies their financial impact. The absence of reimbursement for the obesity indication limits access to these treatments for a large proportion of patients who need them. And when treatment stops for cost reasons, the physiological consequences are identical to those of any other discontinuation.

Which patients are most affected by cost?

The financial barrier does not affect all patients equally. But in a context where treatment is not reimbursed, cost creates a de facto selection that is not based on medical criteria.

Patients who respond well to treatment

Paradoxically, it is sometimes the patients for whom GLP-1 works best who are most affected by financial discontinuation. They have lost weight, adapted their diet, and built a routine — but they cannot sustain a budget of €200 to €400 per month over time. The discontinuation is not a medical choice. It is an economic one.

Patients with a BMI between 27 and 35

These patients are often outside the anticipated reimbursement criteria (BMI ≥ 35) and below the thresholds for bariatric surgery. They find themselves in a blind spot of care: too light for heavy-duty solutions, but with a real need for appetite support.

Patients in the maintenance phase

After successful weight loss on GLP-1, the maintenance phase is critical. The patient has reached their goal but must continue paying for treatment to avoid regain. It is often at this stage that the cost question becomes unsustainable — initial motivation fades, and the monthly budget weighs differently.

A one-time tool vs a recurring treatment: two different economic models

The cost structure of GLP-1s is recurring and indefinite: the patient pays every month, for as long as they wish to maintain the effect. This is consistent with the mechanism of action (the effect is suspensive), but it is also what makes treatment vulnerable to financial erosion.

Other therapeutic approaches operate on a one-time acquisition model: an initial investment, with no recurring monthly cost. This is the case for reusable medical devices, which once acquired, generate no ongoing expenditure.

This difference in economic model is not a clinical argument — it says nothing about comparative efficacy. But it has a direct practical consequence: a one-time-cost tool cannot be discontinued for financial reasons. The patient continues to use it regardless of their budgetary situation.

How to integrate the cost factor into the care strategy?

The question is not whether to choose between GLP-1 treatment and non-pharmacological support. It is about building a pathway that remains functional regardless of how the patient's financial situation evolves.

During GLP-1 treatment

Take advantage of the therapeutic window — the period when appetite is regulated by medication — to consolidate behavioural habits and introduce complementary tools. If discontinuation occurs, the patient already has relays in place.

In anticipation of discontinuation

When the prescriber identifies a risk of financial discontinuation, a structured transition can be planned: progressive dose reduction, reinforced dietary follow-up, and introduction of mechanical satiety support to maintain a sensory reference point during the critical phase.

After discontinuation

For patients who have already stopped and are experiencing regain, non-pharmacological support is not a step backwards. It is a shift towards a different strategy — multi-pathway, combining nutritional follow-up, behavioural support, and mechanical modulation of satiety.

Frequently asked questions: GLP-1 cost and access to treatment

How much does Wegovy® cost in France in 2026?

Pricing varies by dosage and pharmacy. On average, it ranges from €180 to €260/month for initial dosages, and can reach €270 to €370/month at the 2.4 mg maintenance dose. Since 15 June 2026, Wegovy® is reimbursed at 65% (close to 100% under long-term illness status / ALD) for patients with BMI ≥ 40, or ≥ 35 with at least one obesity-related comorbidity. For patients outside these criteria, the full price remains payable in pharmacy.

Is Wegovy® reimbursed by French Social Security?

Yes, since 15 June 2026, following two ministerial decrees of 28 May 2026. Reimbursement is set at 65% (rising close to 100% for patients under long-term illness status / ALD), restricted to adults with a BMI ≥ 40 kg/m², or ≥ 35 kg/m² with at least one obesity-related comorbidity (type 2 diabetes, sleep apnoea, hypertension, etc.), after failure of structured nutritional management. Initial prescription is reserved to hospital specialists (Specialised Obesity Centres / CSO, university hospitals, nutrition or endocrinology departments); renewals can be performed by general practitioners. Patients with a BMI between 27 and 35 without qualifying comorbidity remain outside the reimbursed pathway.

Is Ozempic® cheaper than Wegovy®?

Ozempic® costs between €60 and €120/month and is 30% reimbursed — but only for the type 2 diabetes indication. Its use for obesity is off-label and not reimbursed. The maximum dosage (1 mg) is also lower than Wegovy® (2.4 mg).

Are there non-pharmacological alternatives for appetite regulation?

Appetite regulation relies on multiple physiological pathways. Beyond the hormonal pathway targeted by GLP-1s, the mechanical pathway (gastric distension, mechanoreceptors) and the behavioural pathway (dietary habits, nutritional follow-up) remain available. Certain medical devices aim to support the mechanical perception of satiety within structured care pathways.

Is cost the leading cause of GLP-1 discontinuation?

Cost is among the major factors, alongside adverse effects, supply disruptions, and clinical decisions. In France, the absence of reimbursement for the obesity indication makes it a particularly decisive factor for long-term treatments.

Further reading